Skip to main content
Premium Trial:

Request an Annual Quote

Awaiting IPO, CardioDx Raises $21M in Private Financing

NEW YORK (GenomeWeb) – Cardiovascular molecular diagnostics company CardioDx has raised $21 million toward a targeted goal of $25 million, it disclosed in a regulatory document filed on Wednesday.

A company spokesperson told GenomeWeb Daily News that the firm is "not commenting on its financing activities at this time."

In a document filed with the US Securities and Exchange Commission, the Redwood City, Calif.-based firm said that the type of securities offered was in the form of equity. It also said that 14 investors have participated in the financing so far, though it did not identify them.

CardioDx develops molecular diagnostics with an initial focus on coronary artery diseases, arrhythmia, and heart failure. Its flagship product is Corus CAD, a gene expression-based test for assessing non-diabetic patients who display symptoms suggestive of obstructive CAD.

CardioDx filed for an initial public offering last year of 5 million shares of common stock, but it has yet to go public. In a preliminary prospectus filed in November, the firm said it planned to offer the shares at between $14 and $16 per share. At the midpoint price of $15, the IPO would bring in about $77.3 million in net proceeds if the offering's underwriters exercise their overallotment options in full.

In an SEC document filed in April, CardioDx said it had $3.9 million in cash and cash equivalents and $22.7 million in short-term investments as of the end of 2013.

The company previously had raised $58 million during the summer of 2012. Before that it raised $60 million in 2011, and in 2010 GE Healthcare invested $5 million in the company as part of a Series D financing round.

The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.